Double punch against leukemia: CAR-T cells then stem cell transplant
NCT ID NCT07342244
First seen Jan 18, 2026 · Last updated May 17, 2026 · Updated 19 times
Summary
This study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive specially engineered immune cells (CLL1 CAR-T) to attack the cancer. Then, they get a stem cell transplant from a healthy donor to rebuild a healthy blood system. The goal is to see if this combination is safe and helps patients live longer. The trial plans to enroll 18 adults aged 18 to 75.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.